HCS Pharma utilizes its proprietary BIOMIMESYS® hydroscaffold technology to create 3D cell cultures that accurately replicate the extracellular matrix of various tissues, enhancing the predictive capabilities of drug development. This technology addresses the challenge of high failure rates in clinical trials by providing more relevant in vitro models for assessing drug efficacy and safety.
Funding
$2.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional 2D cell cultures often fail to accurately mimic the complex microenvironment of living tissues, leading to poor predictability in drug development and high failure rates in clinical trials. The absence of a realistic extracellular matrix (ECM) and cell-cell interactions in these models limits their ability to replicate in vivo conditions.
Solution
HCS Pharma offers BIOMIMESYS®, a hydroscaffold technology that creates 3D cell cultures designed to replicate the ECM of various tissues. This technology utilizes a hyaluronic acid-based hydroscaffold to mimic the natural tissue microenvironment, providing a more predictive in vitro model for drug development. By tuning the composition of the BIOMIMESYS® matrix, the cellular microenvironment of specific organs and tissues can be replicated, enhancing the assessment of drug efficacy and safety. The BIOMIMESYS® technology aims to improve the relevance of preclinical studies, leading to better selection of drug candidates and reduced failure rates in clinical trials.
Target Audience
The primary audience includes pharmaceutical companies, biotech firms, and research institutions involved in drug discovery and development, seeking more predictive in vitro models.
Features
- Natural hyaluronic acid-based hydroscaffold that mimics the extracellular matrix (ECM)
- Tunable composition to replicate the microenvironment of different organs and tissues
- Reproduces matrix architecture, cellular organization, and cell-cell/cell-matrix interactions
- Available in organ-specific formulations, including Brain and Liver
- Compatible with primary cells, cell lines, and iPSC-derived cells
- Easy-to-use format with readily available tutorials